EUVIMEDEUVIMED entdecken
Crossref

Psoriasis as a Systemic Immune-Mediated Disease: From Pathogenesis to Targeted Therapy

Anjali Bhardwaj, Nisha Gahlyan, Ranjna Jaglan, Sarita Khatkar, Neelam Malik, Priyanka Rathee

International Journal of Drug Delivery Technology · 19.06.2026 · 16 (56s)

DOI: 10.25258/ijddt.16.56s.63 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 19.06.2026. Verfasst von Anjali Bhardwaj und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a skin condition triggered by the immune system, leading to red, scaly skin. Psoriasis is a skin condition that can cause negative effects on an individual emotionally, socially, psychologically, and even physically. This condition affects people's lives negatively because, apart from the physical discomforts experienced by the affected individuals, psoriasis can be associated with other medical conditions such as arthritis, cardiovascular disorders, and mental disorders. The causes of psoriasis are very complex and include genetic factors, environmental factors, and immunologic factors. In case any of the above occurs, there will be increased production of many inflammatory agents including tumor necrosis factor and interleukins. This leads to various skin complications, such as rapid skin cell proliferation, which can cause skin inflammation. The Psoriasis Area and Severity Index (PASI), which measures the degree of body surface involvement as well as the intensity of clinical characteristics are frequently used to gauge the severity of psoriasis. Treatment plans are customized based on the severity of the illness. Topical medications are usually used to treat mild instances, whereas phototherapy, systemic conventional medications, or targeted biologic treatments may be necessary for moderate-to-severe condition. The treatment of moderate-to-severe psoriasis has changed dramatically in recent years, especially with the introduction of biologic medicines that target the interleukin (IL)-17 and IL-23 pathways. This review emphasizes the significance of individualized treatment programs that maximize clinical success while reducing side effects, highlighting recent advancements in the management of psoriasis. Along with current therapy techniques, which range from traditional methods to next-generation drugs, it also gives a review of the epidemiology, pathophysiology, clinical presentation, and illness spectrum

Zitieren

APA

Bhardwaj, A., Gahlyan, N., Jaglan, R., Khatkar, S., Malik, N., & Rathee, P. (2026). Psoriasis as a Systemic Immune-Mediated Disease: From Pathogenesis to Targeted Therapy. International Journal of Drug Delivery Technology, 16(56s). https://doi.org/10.25258/ijddt.16.56s.63

Vancouver

Bhardwaj A, Gahlyan N, Jaglan R, Khatkar S, Malik N, Rathee P. Psoriasis as a Systemic Immune-Mediated Disease: From Pathogenesis to Targeted Therapy. International Journal of Drug Delivery Technology. 2026;16(56s). doi:10.25258/ijddt.16.56s.63

BibTeX
@article{Bhardwaj2026,
  author = {Bhardwaj, Anjali and Gahlyan, Nisha and Jaglan, Ranjna and Khatkar, Sarita and Malik, Neelam and Rathee, Priyanka},
  title = {Psoriasis as a Systemic Immune-Mediated Disease: From Pathogenesis to Targeted Therapy},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {56s},
  doi = {10.25258/ijddt.16.56s.63}
}
Kostenlos starten →